Trevi Therapeutics, Inc. TRVI

Trevi Therapeutics Inc advances Phase 3 pipeline as detailed in Q2 2026 earnings call highlights. Phase 3 pipeline advancement represents major strategic progress that can significantly alter company trajectory.

Trevi Therapeutics Q2 earnings call highlights detail quarterly financial results, operational updates, and company outlook for TRVI. Q2 earnings updates supply financial metrics and outlook that moderately influence TRVI stock and investor views.

Trevi Therapeutics reported second quarter 2026 financial results and provided business updates. Quarterly results and updates supply performance data that moderately shapes valuation and outlook.

Trevi Therapeutics (TRVI) stock soars as Haduvio targets a $15 billion addressable market. Haduvio access to a $15B market signals major revenue growth and shifts company trajectory.

Trevi Therapeutics shares doubled yet Pivotal bioVenture continued adding to its position, underscoring ongoing investor conviction in the company's prospects. Stock doubling combined with continued venture investment points to moderate short-term sentiment boost without altering core fundamentals.

Trevi Therapeutics outlines commercialization strategy for Haduvio in chronic cough, projecting cash runway through 2030. Strategic product push combined with extended cash runway positions Trevi Therapeutics for significant growth and investor confidence.

Trevi Therapeutics (TRVI) stock rose 5.9% after announcing extension of its cash runway into 2030. Extending cash runway to 2030 bolsters financial stability, reduces funding risks, and supports pipeline advancement, significantly lifting investor sentiment.

Trevi Therapeutics, Inc. shared Q1 2026 earnings call highlights, covering financial results, pipeline progress on Haduvio for pruritus in CKD and PID patients, clinical trial updates, and forward guidance amid ongoing Phase 3 trials. Earnings call summary details financials and pipeline advancements with moderate potential to influence short-term market sentiment and stock performance.

Trevi Therapeutics Q1 earnings call highlights financial results, pipeline updates on Haduvio for pruritus in CKD patients, cash position, and upcoming clinical milestones. Q1 earnings highlights cover financials and pipeline progress with moderate influence on near-term market sentiment and performance.

Trevi Therapeutics reported first quarter 2026 financial results and provided business updates. Quarterly financial results and business updates affect financial performance and investor sentiment moderately.

Trevi Therapeutics, Inc. (TRVI) announces acceptance of an oral presentation and multiple posters at the American Thoracic Society (ATS) 2026 International Conference. Conference acceptance elevates research visibility and credibility in thoracic medicine, potentially influencing investor sentiment and partnerships.

Trevi Therapeutics (TRVI) raised US$173 million through a capital raise and expanded its authorized shares, potentially reshaping its investment narrative amid ongoing clinical developments. $173 million raise provides substantial funding for pipeline advancement, significantly boosting financial runway and investor sentiment despite share dilution.

Trevi Therapeutics, Inc. (TRVI) closed a $173 million underwritten public offering of common stock, with underwriters fully exercising their option to purchase additional shares at the offering price. $173 million capital infusion provides substantial funding to advance clinical programs and extend runway, significantly enhancing financial stability and market position.

Trevi Therapeutics priced a $150 million underwritten offering of common stock. $150 million stock offering provides major capital infusion to fund pipeline development and extend runway, significantly impacting financial position and investor sentiment.

Trevi Therapeutics, Inc. (TRVI) announced a proposed public offering of its common stock to raise capital. Proposed public offering provides funding for operations but dilutes shareholders and pressures stock price significantly.

Trevi Therapeutics (TRVI) achieves FDA End of Phase 2 milestone for IPF chronic cough program, triggering valuation analysis amid positive regulatory progress. FDA End of Phase 2 milestone clears path for Phase 3 trials in IPF chronic cough, significantly enhancing TRVI's development pipeline and investor outlook.

Trevi Therapeutics (TRVI) released its earnings call transcript detailing quarterly financial results, pipeline updates, and management commentary. Earnings transcripts disclose financial performance, clinical progress, and strategic outlook that significantly sway investor sentiment and stock trajectory.

Trevi Therapeutics, Inc. (TRVI) Q4 2025 earnings call summary highlights financial results, pipeline updates, and forward-looking guidance for the biotech firm. Quarterly earnings summaries disclose financial metrics, clinical progress, and strategic plans that significantly influence stock performance and investor outlook.

Trevi Therapeutics Q4 earnings call highlighted financial results, pipeline advancements including Haduvio for pruritus in chronic kidney disease and TSC, raised $50M via equity offering, and projected cash runway into 2026. Earnings highlights reveal moderate pipeline progress and funding extension but no major breakthroughs or revenue shifts to transform trajectory.

Trevi Therapeutics Inc (TRVI) Q4 2025 earnings call highlights strategic advances driving pipeline progress, financial updates, and positive clinical developments. Strategic advances in Q4 2025 earnings call indicate major shifts in pipeline and market positioning for TRVI.

Trevi Therapeutics (TRVI) reported fourth quarter and full-year 2025 financial results alongside business updates. Year-end financial results and business updates represent major milestones that could significantly shape financial performance and strategic outlook.

FDA approves Trevi Therapeutics (TRVI) to advance to Phase 3 trials, sparking valuation analysis amid potential upside for its lead asset. FDA Phase 3 trial approval marks a critical regulatory milestone that could substantially elevate TRVI's valuation and market trajectory.

Trevi Therapeutics completed its End-of-Phase 2 meeting with the FDA, gaining alignment on the development program for idiopathic pulmonary fibrosis-related chronic cough. FDA alignment after End-of-Phase 2 meeting de-risks Phase 3 trials for Trevi's IPF cough program, significantly advancing pipeline and market prospects.

Wall Street analysts expect Trevi Therapeutics (TRVI) stock to rally 102.07%, raising questions about its potential realization. Analysts' 102.07% upside target signals major potential boost to TRVI investor sentiment and stock trajectory.

Trevi Therapeutics, Inc. announced the publication of data from its Phase 2b trial of nalbuphine ER for chronic cough associated with idiopathic pulmonary fibrosis (IPF) in the Journal of the American Medical Association (JAMA). The study demonstrated that nalbuphine ER significantly reduced cough frequency and improved quality of life for patients. This publication is expected to enhance the visibility of Trevi's research and support further development of nalbuphine ER as a treatment option for chronic cough in IPF patients. The publication of positive trial data in a prestigious journal is likely to significantly impact Trevi's market position and investor sentiment.

BioCT has appointed four prominent leaders in the life sciences sector to its Board of Directors, aiming to enhance its strategic direction and support for the biotechnology community. The new board members bring extensive experience and expertise, which is expected to strengthen BioCT's initiatives and collaborations within the industry. The appointment of experienced leaders may positively influence strategic initiatives and collaborations, but the overall impact on Trevi Therapeutics' trajectory is expected to be limited.

Trevi Therapeutics, Inc. (TRVI) received positive feedback from the FDA regarding its End of Phase 2 update for its lead product candidate, Haduvio, aimed at treating chronic cough associated with idiopathic pulmonary fibrosis. Analysts have expressed renewed optimism about the company's prospects following this update, highlighting the potential for Haduvio to address a significant unmet medical need. The FDA's feedback is seen as a crucial step towards advancing the drug into Phase 3 trials, which could enhance TRVI's market position and investor confidence. The FDA's positive feedback and the potential advancement to Phase 3 trials are likely to significantly impact Trevi's future performance and investor sentiment.

Trevi Therapeutics, Inc. is focusing on its Nalbuphine ER cough strategy, aiming to establish a multi-indication moat. The company is exploring the potential of Nalbuphine ER for treating chronic cough, which could diversify its product offerings and enhance its market position. This strategy may lead to significant advancements in the treatment landscape for cough-related conditions, potentially benefiting patients and driving growth for Trevi. The development of a multi-indication strategy with Nalbuphine ER could significantly alter Trevi's market positioning and investor sentiment.

Trevi Therapeutics, Inc. provided strategic updates in anticipation of the Annual LifeSci Partners Corporate Access Event coinciding with the J.P. Morgan Healthcare Conference. The company highlighted its ongoing initiatives and future plans, aiming to enhance investor engagement and showcase its progress in developing treatments for chronic cough and other conditions. The updates may moderately influence investor sentiment and the company's competitive positioning in the healthcare market.

Trevi Therapeutics, Inc. (TRVI) is highlighted as one of MarketBeat’s top-rated small-cap stocks, showcasing its potential for growth and investment appeal. The company focuses on developing therapies for chronic cough and other conditions, positioning itself favorably in the biotech sector. Investors are encouraged to consider TRVI as part of their portfolio due to its promising pipeline and market opportunities. Trevi Therapeutics has a promising pipeline that may moderately influence its financial performance and market positioning.